Omeros and Novo Nordisk Close $2.1B Deal for Rare Disease Asset Zaltenibart

Omeros and Novo Nordisk have closed a deal worth up to $2.1B for the phase 2 asset zaltenibart, in development for rare blood and kidney disorders. The biologic targets the CD22 receptor and is being developed for the treatment of autoimmune hematologic disorders and thrombocytopenia. The deal includes an upfront payment of $900M and potential milestone payments of up to $1.2B.